Jonathan Anker, MD, PhD
Jonathan Anker, MD, PhD, was awarded Mount Sinai’s inaugural Resident/Fellow Article of the Year for 2025 for an article published in Nature Cancer.
The article, titled “Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial,” was published in Nature Cancer on May 9, 2025.
Dr. Anker is a 2025 graduate of The Mount Sinai Hospital Hematology and Medical Oncology Fellowship Program. He is an Instructor in Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai.
The article describes how researchers at the Icahn School of Medicine showed that their custom-made cancer vaccine, in combination with immune checkpoint inhibitor, is safe and able to spark strong immune responses in people with bladder cancer.
Their phase 1 study, led by Nina Bhardwaj, MD, PhD, and Matthew Galsky, MD, adds to growing evidence that personalized vaccines could make existing cancer treatments more safe and effective. Click here to read the news release.
Dr. Anker is a medical oncologist specializing in the care of patients with genitourinary cancers, including bladder, prostate, kidney, and testicular cancer. His research focuses on tumor immunology and optimizing immunotherapeutics through laboratory, translational, and clinical studies.
A collaborative team at Mount Sinai, bringing together experts in immunology, oncology, genetics, and pathology, drove the study. The National Cancer Institute of the National Institutes of Health, the Cancer Research Institute, the Parker Institute of Cancer Immunotherapy, and industry partners supported this study.